These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22211347)

  • 21. Factors affecting noncompliance with buprenorphine maintenance treatment.
    Fareed A; Eilender P; Ketchen B; Buchanan-Cummings AM; Scheinberg K; Crampton K; Nash A; Shongo-Hiango H; Drexler K
    J Addict Med; 2014; 8(5):345-50. PubMed ID: 25072677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Better efficacy of buprenorphine and methadone in opioid dependence. Requirements for abstinence from non-opioids before starting treatment paid off].
    Hoffmann O; Frisell F; Ljungberg T
    Lakartidningen; 2014 Jan 29-Feb 4; 111(5):147-9. PubMed ID: 24624763
    [No Abstract]   [Full Text] [Related]  

  • 24. Buprenorphine for the treatment of opioid dependence in pregnancy.
    Mittal L
    J Perinat Neonatal Nurs; 2014; 28(3):178-84. PubMed ID: 25062519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
    Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
    J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
    Chalhoub RM; Kalivas PW
    Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment.
    Binder P; Messaadi N; Perault-Pochat MC; Gagey S; Brabant Y; Ingrand P
    J Addict Dis; 2016; 35(2):101-8. PubMed ID: 26745033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
    Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
    Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Injection Butorphanol dependence: A case report.
    Shah B; Gupta R; Sarkar S; Balhara YPS
    Asian J Psychiatr; 2018 Jun; 35():45-46. PubMed ID: 29778749
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine.
    Saleh MI
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3935-42. PubMed ID: 25555887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.